<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9387">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05698888</url>
  </required_header>
  <id_info>
    <org_study_id>VP301-001</org_study_id>
    <nct_id>NCT05698888</nct_id>
  </id_info>
  <brief_title>Study of VP301 in Patients With Multiple Myeloma, Lymphoma, or Solid Tumors</brief_title>
  <official_title>A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of VP301 in Patients With Relapsed or Refractory Multiple Myeloma, Lymphoma, or Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Virtuoso BINco, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Virtuoso BINco, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will test the safety, tolerability, and pharmacokinetics of VP301 in patients with&#xD;
      relapsed or refractory multiple myeloma, lymphoma, or solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will test the safety, tolerability, and pharmacokinetics of VP301 in patients with&#xD;
      relapsed or refractory multiple myeloma, lymphoma, or solid tumors. This study will be&#xD;
      conducted in two parts:&#xD;
&#xD;
      Dose Escalation - This part will evaluate increasing doses of VP301 to identify the maximum&#xD;
      tolerated dose (MTD) or recommended Phase 2 dose (RP2D). The first patient enrolled on the&#xD;
      study will receive the lowest dose of VP301. Once this dose is shown to be safe, an&#xD;
      additional patient will be enrolled at the next higher dose. Patients will continue to be&#xD;
      enrolled into either single or multiple patient groups receiving increasing doses until the&#xD;
      MTD or RP2D is reached.&#xD;
&#xD;
      Dose Expansion - Patients with relapsed myeloma and lymphoma will be enrolled and treated&#xD;
      with VP301 at the MTD or RP2D.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 29, 2022</start_date>
  <completion_date type="Anticipated">September 12, 2026</completion_date>
  <primary_completion_date type="Anticipated">March 21, 2026</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Following completion of the dose escalation phase of the study and determination of maximum tolerated dose or recommended phase 2 dose, patients will be enrolled into dose expansion.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of General Toxicity</measure>
    <time_frame>through study completion, an average of 30 months</time_frame>
    <description>Incidence of treatment-emergent serious AEs including toxicity and change from baseline in safety parameters</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of Dose Limiting Toxicity</measure>
    <time_frame>Over the first 21 days of VP301 dosing</time_frame>
    <description>Incidence of dose limiting toxicity during cycle 1 of dose escalation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum concentrations of VP301</measure>
    <time_frame>through study completion, an average of 30 months</time_frame>
    <description>Change from baseline in serum levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antidrug and neutralizing antibodies</measure>
    <time_frame>through study completion, an average of 30 months</time_frame>
    <description>Change from baseline in serum levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response</measure>
    <time_frame>through study completion, an average of 30 months</time_frame>
    <description>Assessed by IMWG for multiple myeloma, the Lugano criteria for lymphoma or RECIST 1.1 for solid tumors</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best response</measure>
    <time_frame>through study completion, an average of 30 months</time_frame>
    <description>Assessed by IMWG for multiple myeloma, the Lugano criteria for lymphoma or RECIST 1.1 for solid tumors</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response and duration of response</measure>
    <time_frame>through study completion, an average of 30 months</time_frame>
    <description>Assessed by IMWG for multiple myeloma or the Lugano criteria for lymphoma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>through study completion, an average of 30 months</time_frame>
    <description>Assessed by IMWG for multiple myeloma or the Lugano criteria for lymphoma</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Tumor expression</measure>
    <time_frame>through study completion, an average of 30 months</time_frame>
    <description>Evaluate ICAM-1 and CD38 expression with clinical outcomes</description>
  </other_outcome>
  <other_outcome>
    <measure>Immunoglobulins</measure>
    <time_frame>through study completion, an average of 30 months</time_frame>
    <description>Evaluate quantitative immunoglobulins with clinical outcomes</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Solid Tumors, Adult</condition>
  <condition>Multiple Myeloma</condition>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>VP301 (Dose Escalation)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible patients will receive VP301 administered as an IV infusion weekly for 6 weeks then every 2 weeks. Patients will be enrolled into escalating dose levels during the Dose Escalation period of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VP301 (Dose Expansion)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible patients will receive VP301 administered as an IV infusion weekly for 6 weeks then every 2 weeks. Patients will receive the maximum tolerated dose or recommended phase 2 dose during the Dose Expansion period of the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VP301</intervention_name>
    <description>VP301 is an afucosylated humanized Fc-modified immunoglobulin G1 (IgG1) bispecific antibody targeting CD38 and ICAM-1.</description>
    <arm_group_label>VP301 (Dose Escalation)</arm_group_label>
    <arm_group_label>VP301 (Dose Expansion)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologic diagnosis of a refractory solid tumor, refractory myeloma or lymphoma with&#xD;
             measurable or evaluable disease&#xD;
&#xD;
          -  Patients must have progressed following all therapies of known, potential clinical&#xD;
             benefit, or for whom treatments of known clinical benefit are contraindicated.&#xD;
&#xD;
          -  Adequate kidney, liver, and hematologic function&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active brain metastases and history of leptomeningeal metastases.&#xD;
&#xD;
          -  Myeloma patients with plasmacytoma as only measurable disease&#xD;
&#xD;
          -  Non-secretory myeloma&#xD;
&#xD;
          -  Patients with advanced metastatic, symptomatic, visceral spread who are at risk of&#xD;
             life-threatening complications&#xD;
&#xD;
          -  Active or chronic, uncontrolled bacterial, viral, or fungal infection(s)&#xD;
&#xD;
          -  Abnormal ECG&#xD;
&#xD;
          -  Has clinically significant cardiovascular disease&#xD;
&#xD;
          -  Additional active malignancy that may confound the assessment of the study endpoints&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Known seropositivity for HIV (human immunodeficiency virus) or active hepatitis B or&#xD;
             hepatitis C&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Eryn Bagley</last_name>
    <phone>650-204-9853</phone>
    <email>ebagley@inclin.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jill Abbey</last_name>
    <phone>650-666-2753</phone>
    <email>jabbey@virtuosotherapeutics.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>NEXT Oncology</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cynthia DeLeon</last_name>
      <phone>210-580-9521</phone>
      <email>cdeleon@nextoncology.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2023</verification_date>
  <study_first_submitted>December 12, 2022</study_first_submitted>
  <study_first_submitted_qc>January 16, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 26, 2023</study_first_posted>
  <last_update_submitted>January 16, 2023</last_update_submitted>
  <last_update_submitted_qc>January 16, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">January 26, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

